• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

JDRF Alarmed by Extension of UnitedHealthcare–Metronic Pact to Youth With Type 1 Diabetes

Evidence-Based Diabetes ManagementMarch 2019
Volume 25
Issue 4

Nearly 3 years after UnitedHealthcare set off a firestorm among the type 1 diabetes (T1D) community by naming Medtronic its preferred supplier of insulin pumps for adults, a fresh wave of protest has erupted after the payer extended the pact to youth, starting at age 7. The change was announced in a UnitedHealthcare bulletin February 1, 2019.

Nearly 3 years after UnitedHealthcare set off a firestorm among the type 1 diabetes (T1D) community by naming Medtronic its preferred supplier of insulin pumps for adults,1 a fresh wave of protest has erupted after the payer extended the pact to youth, starting at age 7. The change was announced in a UnitedHealthcare bulletin February 1, 2019.2

The change follows the FDA’s expanded approval for the Medtronic MiniMed 670G for people with T1D aged 7 to 13 on June 21, 2018. The 670G, a hybrid closed-loop system, was previously approved for people with T1D aged 14 and older.3

JDRF, the advocacy and research organization previously known as the Juvenile Diabetes Research Foundation, issued a statement February 4, 2019, calling on UnitedHealthcare to reverse its decision, saying insurance restrictions “are bad for people with T1D, bad for children and their caregivers, and bad for our healthcare system.”4 In 2017, JDRF launched a campaign, Coverage2Control, to highlight the need for people with T1D to have choices in insulin, diabetes technology, and supplies like test strips, so that each person with T1D can select the products that best meets his or her needs.5

As was the case with the original policy change, the T1D community was taken by surprise, Cynthia Rice, vice president for advocacy and policy for JDRF, said in an interview with Evidence-Based Diabetes-Management™ (EBDM). Expanding the policy to include youth aged 7 and older happened despite extensive talks with the payer that took place after the May 2016 decision, she said.

“This really does matter to our community,” she said. “These technologies are important to managing type 1 diabetes. People feel strongly they want to use what works for them, and they should make this decision themselves with their doctor.”

In an email, a UnitedHealthcare spokeswoman told EBDM that patient safety and helping those with diabetes avoid dangerous high and low blood glucose levels were the key factors in the decision to make the MiniMed 670G system the preferred product for people with T1D who are age 7 and older. The policy applies to those prescribed an insulin pump for the first time and those whose pump must be replaced after an older pump is out of warranty, according to the policy.

“Pediatric patients who are currently using a non-Medtronic pump may remain on that pump in conjunction with the physician’s treatment plan,” UnitedHealthcare spokeswoman Tracey Lemper said.

A fact sheet provided by the payer stated that there is no change in coverage for those using nondurable tubeless pumps. However, UnitedHealthcare declined to clarify what happens if a person temporarily stops using a nondurable pump and uses multiple daily injections instead. Some people with T1D occasionally switch back to injections if they cannot afford the cost sharing to replace a pump or if they want to maintain the ability to manage their diabetes with insulin injections.

As it did in May 2016, UnitedHealthcare announced a clinical review policy that will allow physicians to appeal for their patients to use other pumps in special circumstances.2 However, Rice said in the interview that successful appeals are rare, and UnitedHealthcare declined to release figures on the rate of successful appeals.

The UnitedHealthcare fact sheet stated that 9 of 10 enrollees who use an insulin pump already use a Medtronic pump. It is not clear how many youths with T1D will be affected by the new policy.

In July 2018, UnitedHealthcare released results from 6000 participants who used Medtronic pumps over the first year of the preferred arrangement. The statement said there were 27% fewer preventable hospital admissions compared with UnitedHealthcare beneficiaries using multiple daily injections.6

However, JDRF’s Rice told EBDM that statistic only measures how Medtronic users compare with those who aren’t using insulin pumps. A more meaningful analysis would examine how people fared after they were forced to switch once a warranty ran out or how the outcomes of this group compared with those from a payer that allows people with T1D to use the insulin pump of their choice.

Rice said thus far that no one has released a study comparing outcomes for different insulin pump brands head-to-head. But advocates have been clear that the issue is not Medtronic’s technology. Many leaders in the T1D community credit the company for pursuit of the 670G. The issue, they say, is that different products emphasize different features, such as alarms or alerts to family and caregivers, and features that matter greatly to one person may matter less to others.

In 2016, T1D advocates warned that the UnitedHealthcare—Medtronic relationship could affect competition and innovation in the diabetes technology marketplace. In 2017, Roche and Johnson & Johnson stopped selling insulin pumps in the United States and transferred their users over to Medtronic for customer service.7 However, in recent years Medicare has expanded coverage for continuous glucose monitors (CGMs). Dexcom followed by Abbott’s Freestyle Libre received coverage after the CGM received FDA approval.8,9 Then Medicare covered the Omnipod insulin pump after years of interpreting durable medical equipment rules in a way unfavorable to the tubeless pump.10

Since the UnitedHealthcare decision, innovation has continued.11 There is considerable anticipation about the partnership between Insulet, maker of the Omnipod pump, and Tidepool, which is working to get an automated insulin delivery app through the FDA, as well as Omnipod’s work with Dexcom.12

Rice said it’s important that payers remain open to covering different technologies. “The reason why a doctor might choose one insulin pump over another depends on a lot of factors—how well the sensor works, the emergency alerts to let people know they’re about to have a severe low blood sugar,” she said. “UnitedHealthcare is really an outlier here… That’s why we’re advocating for them to join the rest of the industry.” REFERENCES:

  1. Caffrey M. JDRF Alarmed by Extension of UnitedHealthcare—Medtronic Pact to Youth With Type 1 Diabetes. The American Journal of Managed Care® website. ajmc.com/focus-of-the-week/jdrf-alarmed-by-extension-of-unitedhealthcaremedtronic-pact-to-youth-with-type1diabetes. Published May 10, 2016. February 4, 2019.
  2. MiniMed 670G System from Medtronic more widely available. UnitedHealthcare website. uhcprovider.com/ content/dam/provider/docs/public/resources/news/2019/network-bulletin/February-Interactive-Network-Bulletin-2019.pdf . Published February 1, 2019. Accessed February 4, 2019.
  3. FDA approves automated insulin delivery and monitoring system for use in younger pediatric patients [press release]. Silver Spring, MD: FDA; June 21, 2018. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611475.htm. Accessed February 22, 2019.
  4. JDRF statement on insulin pump agreement with Medtronic [press release]. New York, NY: JDRF; February 4, 2019. jdrf.org/press-releases/jdrf-statement-on-united-healthcare-insulin-pump-agreement-with-medtronic/. Accessed February 22, 2019.
  5. JDRF. Coverage to control. JDRF website. jdrf.org/community/take-action/coverage2control/. Accessed February 22, 2019.
Related Videos
Ian Neeland, MD
Chase D. Hendrickson, MD, MPH
Steven Coca, MD, MS, Icahn School of Medicine, Mount Sinai
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Susan Spratt, MD, senior medical director, Duke Population Health Management Office, associate professor of medicine, division of Endocrinology, Metabolism, and Nutrition,
Stephen Nicholls, MD, Monash University and Victorian Heart Hospital
Amal Agarwal, DO, MBA
Dr Robert Groves
Dr Robert Groves
Related Content
© 2024 MJH Life Sciences
All rights reserved.